These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
238 related articles for article (PubMed ID: 38701030)
1. Costs and health care resource utilization among Medicare beneficiaries diagnosed with chronic lymphocytic leukemia. Lee TY; Johnson A; Cooke CE; Yared JA; Summers A; Yang K; Liu S; Tang B; Onukwugha E J Manag Care Spec Pharm; 2024 May; 30(5):430-440. PubMed ID: 38701030 [TBL] [Abstract][Full Text] [Related]
2. Medication Adherence, Health Care Utilization, and Costs Among Patients Initiating Oral Oncolytics for Multiple Myeloma or Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. Dashputre AA; Gatwood KS; Gatwood J J Manag Care Spec Pharm; 2020 Feb; 26(2):186-196. PubMed ID: 32011965 [TBL] [Abstract][Full Text] [Related]
3. Healthcare resource utilization and costs associated with first-line ibrutinib compared to chemoimmunotherapy treatment among Medicare beneficiaries with chronic lymphocytic leukemia. Huang Q; Emond B; Lafeuille MH; Gupta D; Lefebvre P; Sundaram M; Mato A Curr Med Res Opin; 2020 Dec; 36(12):2009-2018. PubMed ID: 33044848 [TBL] [Abstract][Full Text] [Related]
4. Assessing the association between medication adherence, as defined in quality measures, and disease-state control, health care utilization, and costs in a retrospective database analysis of Medicare supplemental beneficiaries using statin medications. Axon DR; Vaffis S; Chinthammit C; Lott BE; Taylor AM; Pickering M; Black H; Warholak T; Campbell PJ J Manag Care Spec Pharm; 2020 Dec; 26(12):1529-1537. PubMed ID: 33251989 [No Abstract] [Full Text] [Related]
5. Real-world comparison of health care costs of venetoclax-obinutuzumab vs Bruton's tyrosine kinase inhibitor use among US Medicare beneficiaries with chronic lymphocytic leukemia in the frontline setting. Huntington SF; Manzoor BS; Jawaid D; Puckett JT; Emechebe N; Ravelo A; Kamal-Bahl S; Doshi JA J Manag Care Spec Pharm; 2024 Oct; 30(10):1106-1116. PubMed ID: 39046941 [TBL] [Abstract][Full Text] [Related]
6. Real-World Economic Outcomes During Time on Treatment Among Patients Who Initiated Sunitinib or Pazopanib as First Targeted Therapy for Advanced Renal Cell Carcinoma: A Retrospective Analysis of Medicare Claims Data. Vogelzang NJ; Pal SK; Ghate SR; Li N; Swallow E; Peeples M; Zichlin ML; Meiselbach MK; Perez JR; Agarwal N J Manag Care Spec Pharm; 2018 Jun; 24(6):525-533. PubMed ID: 29799328 [TBL] [Abstract][Full Text] [Related]
7. Time to Next Treatment, Health Care Resource Utilization, and Costs Associated with Ibrutinib Use Among U.S. Veterans with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: A Real-World Retrospective Analysis. Huang Q; Borra S; Li J; Wang L; Shrestha S; Sundaram M; Janjan N J Manag Care Spec Pharm; 2020 Oct; 26(10):1266-1275. PubMed ID: 32880204 [TBL] [Abstract][Full Text] [Related]
8. Patterns of national emergency department utilization by fee-for-service Medicare beneficiaries with dementia. Bowman JK; Ritchie CS; Ouchi K; Tulsky JA; Teno JM J Am Geriatr Soc; 2024 Oct; 72(10):3140-3148. PubMed ID: 38838377 [TBL] [Abstract][Full Text] [Related]
9. Burden of chronic obstructive pulmonary disease in Medicare beneficiaries residing in long-term care facilities. Simoni-Wastila L; Blanchette CM; Qian J; Yang HW; Zhao L; Zuckerman IH; Pak GH; Silver H; Dalal AA Am J Geriatr Pharmacother; 2009 Oct; 7(5):262-70. PubMed ID: 19948302 [TBL] [Abstract][Full Text] [Related]
10. Economic burden of irritable bowel syndrome with constipation: a retrospective analysis of health care costs in a commercially insured population. Doshi JA; Cai Q; Buono JL; Spalding WM; Sarocco P; Tan H; Stephenson JJ; Carson RT J Manag Care Spec Pharm; 2014 Apr; 20(4):382-90. PubMed ID: 24684643 [TBL] [Abstract][Full Text] [Related]
11. Occult, undiagnosed obstructive sleep apnea is associated with increased health care resource utilization and costs among older adults with comorbid depression: a retrospective cohort study among Medicare beneficiaries. Wickwire EM; Albrecht JS J Clin Sleep Med; 2024 May; 20(5):817-819. PubMed ID: 38205933 [TBL] [Abstract][Full Text] [Related]
12. Healthcare utilization and costs associated with COPD among SEER-Medicare beneficiaries with NSCLC. Shah S; Blanchette CM; Coyle JC; Kowalkowski M; Arthur ST; Howden R J Med Econ; 2018 Sep; 21(9):861-868. PubMed ID: 29857784 [TBL] [Abstract][Full Text] [Related]
13. Health Care Resource Utilization Associated With Parkinson Disease Among Medicare Beneficiaries. Gandhi AB; Onukwugha E; Albarmawi H; Johnson A; Myers DE; Gray D; Alvir J; Hynicka L; Shulman LM Neurology; 2021 Aug; 97(6):e597-e607. PubMed ID: 34045274 [TBL] [Abstract][Full Text] [Related]
14. Real-world treatment patterns, health care resource utilization, and costs in a US Medicare population with bronchiectasis. Tkacz J; Lewing B; Feliciano J; Mohanty M; Lauterio M; Fucile S; Barker A J Manag Care Spec Pharm; 2024 Sep; 30(9):967-977. PubMed ID: 39213146 [TBL] [Abstract][Full Text] [Related]
15. Assessing health care resource use, outcomes, and costs among Medicaid beneficiaries receiving factor IX prophylaxis for hemophilia B. Pauly N; Burrell A; Drelich D; Zhang X; Thiruvillakkat K; Nysenbaum J; Fiori A; Yan S J Manag Care Spec Pharm; 2024 Oct; 30(10):1095-1105. PubMed ID: 38923896 [TBL] [Abstract][Full Text] [Related]
16. Health care utilization and costs of idiopathic pulmonary fibrosis in U.S. Medicare beneficiaries aged 65 years and older. Collard HR; Chen SY; Yeh WS; Li Q; Lee YC; Wang A; Raghu G Ann Am Thorac Soc; 2015 Jul; 12(7):981-7. PubMed ID: 25923447 [TBL] [Abstract][Full Text] [Related]
17. Healthcare Utilization and Costs During the Initial Phase of Care Among Elderly Women With Breast Cancer. Vyas A; Madhavan SS; Sambamoorthi U; Pan XL; Regier M; Hazard H; Kalidindi S J Natl Compr Canc Netw; 2017 Nov; 15(11):1401-1409. PubMed ID: 29118232 [No Abstract] [Full Text] [Related]
18. Economic and Clinical Burden of Acute Myeloid Leukemia Episodes of Care in the United States: A Retrospective Analysis of a Commercial Payer Database. Pandya BJ; Chen CC; Medeiros BC; McGuiness CB; Wilson SD; Walsh EH; Wade RL J Manag Care Spec Pharm; 2020 Jul; 26(7):849-859. PubMed ID: 32281456 [TBL] [Abstract][Full Text] [Related]
19. Health Care Resource Utilization and Costs Among Newly Diagnosed and Oral Anticoagulant-Naive Nonvalvular Atrial Fibrillation Patients Treated with Dabigatran or Warfarin in the United States. Jain R; Fu AC; Lim J; Wang C; Elder J; Sander SD; Tan H J Manag Care Spec Pharm; 2018 Jan; 24(1):73-82. PubMed ID: 29290177 [TBL] [Abstract][Full Text] [Related]
20. The Economic Burden of Nocturia on the U.S. Health Care System and Society: A National Health and Nutrition Examination Survey Analysis. Jhaveri J; Gauthier-Loiselle M; Gagnon-Sanschagrin P; Wu EQ J Manag Care Spec Pharm; 2019 Dec; 25(12):1398-1408. PubMed ID: 31566054 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]